Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea.
These authors contributed equally to this work.
Mol Cells. 2021 Aug 31;44(8):580-590. doi: 10.14348/molcells.2021.0101.
Patients with severe asthma have unmet clinical needs for effective and safe therapies. One possibility may be mesenchymal stem cell (MSC) therapy, which can improve asthma in murine models. However, it remains unclear how MSCs exert their beneficial effects in asthma. Here, we examined the effect of human umbilical cord blood-derived MSCs (hUC-MSC) on two mouse models of severe asthma, namely, Alternaria alternata-induced and house dust mite (HDM)/diesel exhaust particle (DEP)-induced asthma. hUC-MSC treatment attenuated lung type 2 (Th2 and type 2 innate lymphoid cell) inflammation in both models. However, these effects were only observed with particular treatment routes and timings. co-culture showed that hUC-MSC directly downregulated the interleukin (IL)-5 and IL-13 production of differentiated mouse Th2 cells and peripheral blood mononuclear cells from asthma patients. Thus, these results showed that hUC-MSC treatment can ameliorate asthma by suppressing the asthmogenic cytokine production of effector cells. However, the successful clinical application of MSCs in the future is likely to require careful optimization of the route, dosage, and timing.
患有严重哮喘的患者存在对有效和安全治疗方法的未满足的临床需求。间充质干细胞（MSC）疗法可能是一种可能性，它可以改善哮喘的啮齿动物模型。然而，间充质干细胞如何发挥其在哮喘中的有益作用仍不清楚。在这里，我们研究了人脐带血来源的间充质干细胞（hUC-MSC）对两种严重哮喘小鼠模型（Alternaria alternata 诱导和屋尘螨（HDM）/柴油废气颗粒（DEP）诱导的哮喘）的影响。hUC-MSC 治疗减轻了两种模型中的肺 2 型（Th2 和 2 型先天淋巴样细胞）炎症。然而，这些作用仅在特定的治疗途径和时间观察到。共培养表明，hUC-MSC 可直接下调分化的小鼠 Th2 细胞和哮喘患者外周血单核细胞产生的白细胞介素（IL）-5 和 IL-13。因此，这些结果表明 hUC-MSC 治疗可以通过抑制效应细胞的哮喘发病细胞因子产生来改善哮喘。然而，间充质干细胞在未来的临床应用中很可能需要仔细优化途径、剂量和时间。
